BMB Reports

Korean Society for Biochemistry and Molecular Biology (생화학분자생물학회)
권호 표지
DOI QR코드

DOI QR Code

Inhibition of protein tyrosine phosphatase non-receptor type 2 by PTP inhibitor XIX: Its role as a multiphosphatase inhibitor

  • Received : 2017.01.05
  • Accepted : 2017.02.20
  • Published : 2017.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Protein tyrosine phosphatases (PTPs) play crucial roles in signal transduction and their functional alteration has been detected in many diseases. PTP inhibitors have been developed as therapeutic drugs for diseases that are related to the activity of PTPs. In this study, PTP inhibitor XIX, an inhibitor of CD45 and PTEN, was investigated whether it inhibits other PTPs. Protein tyrosine phosphatase non-receptor type 2 (PTPN2) was selectively inhibited by the inhibitor in a competitive manner. Drug affinity responsive target stability (DARTS) analysis showed that the inhibitor induces conformational changes in PTPN2. Phosphorylation levels of signal transducer and activator of transcription 3 (STAT3) at Tyr-705, a crucial site for STAT3 activation and target site of PTPN2, decreased upon exposure to the inhibitor. Our results suggest that PTP inhibitor XIX might be considered as an effective regulator of PTPN2 for treating diseases related to PTPN2.

Keywords

References

  1. Hunter T (2000) Signaling-2000 and Beyond. Cell 100, 113-127 https://doi.org/10.1016/S0092-8674(00)81688-8
  2. Ciesla J, Fraczyk T and Rode W (2011) Phosphorylation of basic amino acid residues in proteins: important but easily missed. Acta Biochim Pol 58, 137-148
  3. Barford D, Das AK and Egloff MP (1998) The structure and mechanism of protein phosphatases: insights into catalysis and regulation. Annu Rev Biophys Biomol Struct 27, 133-164 https://doi.org/10.1146/annurev.biophys.27.1.133
  4. Alonso A, Sasin J, Bottini N et al (2004) Protein tyrosine phosphatases in the human genome. Cell 117, 699-711 https://doi.org/10.1016/j.cell.2004.05.018
  5. Bononi A, Agnoletto C, De Marchi E et al (2011) Protein kinases and phosphatases in the control of cell fate. Enzyme Res 2011, 329098
  6. Heneberg P (2009) Use of protein tyrosine phosphatase inhibitors as promising targeted therapeutic drugs. Curr Med Chem 16, 706-733 https://doi.org/10.2174/092986709787458407
  7. Zhang ZY (2002) Protein tyrosine phosphatases: structure and function, substrate specificity, and inhibitor development. Annu Rev Pharmacol Toxicol 42, 209-234 https://doi.org/10.1146/annurev.pharmtox.42.083001.144616
  8. Scott LM, Lawrence HR, Sebti SM, Lawrence NJ and Wu J (2010) Targeting protein tyrosine phosphatases for anticancer drug discovery. Curr Pharm Des 16, 1843-1862 https://doi.org/10.2174/138161210791209027
  9. Urbanek RA, Suchard SJ, Steelman GB et al (2001) Potent reversible inhibitors of the protein tyrosine phosphatase CD45. J Med Chem 44, 1777-1793 https://doi.org/10.1021/jm000447i
  10. Spinelli L, Lindsay YE and Leslie NR (2015) PTEN inhibitors: an evaluation of current compounds. Adv Biol Regul 57, 102-111 https://doi.org/10.1016/j.jbior.2014.09.012
  11. Li Y, Jia Y, Pichavant M et al (2009) Targeted deletion of tumor suppressor PTEN augments neutrophil function and enhances host defense in neutropenia-associated pneumonia. Blood 113, 4930-4941 https://doi.org/10.1182/blood-2008-06-161414
  12. Rosivatz E, Matthews JG, McDonald NQ et al (2006) A small molecule inhibitor for phosphatase and tensin homologue deleted on chromosome 10 (PTEN). ACS Chem Biol 1, 780-790 https://doi.org/10.1021/cb600352f
  13. Chang J, Kim Y and Kwon HJ (2016) Advances in identification and validation of protein targets of natural products without chemical modification. Nat Prod Rep 33, 719-730 https://doi.org/10.1039/C5NP00107B
  14. Garcia-Carreno FL (1992) Protease inhibition in theory and practice. Biotechnology Education 3, 145-150
  15. Lee H, Morales LD, Slaga TJ and Kim DJ (2015) Activation of T-cell protein-tyrosine phosphatase suppresses keratinocyte survival and proliferation following UVB irradiation. J Biol Chem 290, 13-24 https://doi.org/10.1074/jbc.M114.611681
  16. Kok CH, Leclercq T, Watkins DB et al (2014) Elevated PTPN2 expression is associated with inferior molecular response in de-novo chronic myeloid leukaemia patients. Leukemia 28, 702-705 https://doi.org/10.1038/leu.2013.329
  17. Yu W, Hegarty JP, Berg A et al (2012) PTPN2 is associated with Crohn's disease and its expression is regulated by NKX2-3. Dis Markets 32, 83-91 https://doi.org/10.1155/2012/340204
  18. Wu Z, Chen H, Sun F et al (2014) PTPN2 rs1893217 single-nucleotide polymorphism is associated with risk of Behcet's disease in a Chinese Han population. Clin Exp Rheumatol 32, S20-26
  19. Tierno MB, Johnston PA, Foster C et al (2007) Development and optimization of high-throughput in vitro protein phosphatase screening assays. Nat Protoc 2, 1134-1144 https://doi.org/10.1038/nprot.2007.155
  20. Shi Z, Tabassum S, Jiang W et al (2007) Identification of a potent inhibitor of human dual-specific phosphatase, VHR, from computer-aided and NMR-based screening to cellular effects. Chembiochem 8, 2092-2099 https://doi.org/10.1002/cbic.200700397

Cited by

  1. PTP Inhibitor XIX Inhibits DUSP22 by Conformational Change vol.40, pp.2, 2019, https://doi.org/10.1002/bkcs.11651